[{"@context":"http:\/\/schema.org\/","@type":"BlogPosting","@id":"https:\/\/wiki.edu.vn\/en\/wiki19\/gemoab-monoclonals-wikipedia\/#BlogPosting","mainEntityOfPage":"https:\/\/wiki.edu.vn\/en\/wiki19\/gemoab-monoclonals-wikipedia\/","headline":"GEMoaB Monoclonals – Wikipedia","name":"GEMoaB Monoclonals – Wikipedia","description":"before-content-x4 From Wikipedia, the free encyclopedia after-content-x4 GEMoaB is a biopharmaceutical company based in Dresden\/Germany. The company has a broad","datePublished":"2015-10-27","dateModified":"2015-10-27","author":{"@type":"Person","@id":"https:\/\/wiki.edu.vn\/en\/wiki19\/author\/lordneo\/#Person","name":"lordneo","url":"https:\/\/wiki.edu.vn\/en\/wiki19\/author\/lordneo\/","image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/c9645c498c9701c88b89b8537773dd7c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c9645c498c9701c88b89b8537773dd7c?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Enzyklop\u00e4die","logo":{"@type":"ImageObject","@id":"https:\/\/wiki.edu.vn\/wiki4\/wp-content\/uploads\/2023\/08\/download.jpg","url":"https:\/\/wiki.edu.vn\/wiki4\/wp-content\/uploads\/2023\/08\/download.jpg","width":600,"height":60}},"image":{"@type":"ImageObject","@id":"https:\/\/en.wikipedia.org\/wiki\/Special:CentralAutoLogin\/start?type=1x1","url":"https:\/\/en.wikipedia.org\/wiki\/Special:CentralAutoLogin\/start?type=1x1","height":"1","width":"1"},"url":"https:\/\/wiki.edu.vn\/en\/wiki19\/gemoab-monoclonals-wikipedia\/","about":["Wiki"],"wordCount":1707,"articleBody":"     (adsbygoogle = window.adsbygoogle || []).push({});before-content-x4From Wikipedia, the free encyclopedia       (adsbygoogle = window.adsbygoogle || []).push({});after-content-x4GEMoaB is a biopharmaceutical company based in Dresden\/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.[2][3]       (adsbygoogle = window.adsbygoogle || []).push({});after-content-x4Table of ContentsCompany background[edit]Scientific and strategic board[edit]Co-operations[edit]Drugs currently under development[edit]Literatur[edit]See also[edit]References[edit]External links[edit]Company background[edit]To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR\/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR\/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.[4]Scientific and strategic board[edit]The company’s scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob L\u00f6wenberg (The Netherlands) as well as Thomas de Maizi\u00e8re, Member of Parliament (Germany).[5]Co-operations[edit]Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.[6]       (adsbygoogle = window.adsbygoogle || []).push({});after-content-x4Drugs currently under development[edit]GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AML[7][8]GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumours[9]UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomasUniCAR-T-PSMA for the treatment of a number of PSMA expressing tumoursLiteratur[edit]Nicola Mitwasi et al.: “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells In:  Nature Scientific Reports, Band 10, 2020, S.\u00a02141. doi:10.1038\/s41598-020-59082-4, PMID\u00a032034289.Loff, S., Meyer, J.-E., Dietrich, J., Spehr, J., Julia, R., von Bonin, M., Gr\u00fcnder, C., Franke, K., Feldmann, A., Bachmann, M., Ehninger, G., Ehninger, A., Cartellieri, M.: Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia In: Blood, 132, 2018, S.\u00a0964-964. doi:10.1182\/blood-2018-99-113288.Arndt, C., Feldmann, A., Koristka, S., Schafer, M., Bergmann, R., Mitwasi, N., Berndt, N., Bachmann, D., Kegler, A., Schmitz, M., Puentes-Cala, E., Soto, J.A., Ehninger, G., Pietzsch, J., Liolios, C., Wunderlich, G., Kotzerke, J., Kopka, K., Bachmann, M.: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR In: Oncoimmunology, Band 8, 2019, Article: 1659095. doi:10.1080\/2162402X.2019.1659095, PMID\u00a031646084.C. Arndt, M. von Bonin et al.: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. In: Leukemia, Band 27, Nummer 4, April 2013, S.\u00a0964\u2013967, doi:10.1038\/leu.2013.18, PMID\u00a023325142.See also[edit]References[edit]^ Leadership Team Leadership Team, Company Website, Retrieved: July 15, 2021^ Get to know GEMoaB, Company Website, Retrieved: May 11, 2020^ “GEMoaB Announces First Patient Apheresed in a Phase IA Study with Lead Product Candidate from Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed\/Refractory Acute Leukemias”. chemie-link.de. 9 March 2020. Retrieved 11 May 2020.^ M. Cartellieri, A. Feldmann et al: Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. In: Blood Cancer Journal. Band 6, Nummer 8, 08 2016, S.\u00a0e458, doi:10.1038\/bcj.2016.61, PMID\u00a027518241, PMC\u00a05022178.^ Scientific and Strategic Advisory Board, Company Website, Retrieved: May 11, 2020^ Our Partners, Company Website, Retrieved: May 11, 2020^ AML: GEM333-01, Nationales Centrum f\u00fcr Tumorerkrankungen Dresden, Retrieved: May 11, 2020^ Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia, clinicaltrials.gov, Retrieved: May 11, 2020^ Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker, clinicaltrials.gov, Retrieved: May 11, 2020External links[edit]       (adsbygoogle = window.adsbygoogle || []).push({});after-content-x4"},{"@context":"http:\/\/schema.org\/","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https:\/\/wiki.edu.vn\/en\/wiki19\/#breadcrumbitem","name":"Enzyklop\u00e4die"}},{"@type":"ListItem","position":2,"item":{"@id":"https:\/\/wiki.edu.vn\/en\/wiki19\/gemoab-monoclonals-wikipedia\/#breadcrumbitem","name":"GEMoaB Monoclonals – Wikipedia"}}]}]